Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer

Nearly 45% of colorectal cancer (CRC) patients harbor a mutation in their KRAS gene for which, despite many years of research, there are still no targeted therapies available. Protein Arginine Methyltransferase 5 (PRMT5) is a transcription regulator for multiple cellular processes that is currently...

Descripción completa

Detalles Bibliográficos
Autores principales: Shifteh, David, Sapir, Tzuriel, Pahmer, Moshe, Haimowitz, Adam, Goel, Sanjay, Maitra, Radhashree
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465151/
https://www.ncbi.nlm.nih.gov/pubmed/32731506
http://dx.doi.org/10.3390/cancers12082091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465151/
https://www.ncbi.nlm.nih.gov/pubmed/32731506
http://dx.doi.org/10.3390/cancers12082091

Ejemplares similares